Wockhardt Hospital, SOBO Launches a Diabetes Clinic Powered by Wellthy Therapeutics

Wednesday, November 21, 2018 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

MUMBAI, November 21, 2018 /PRNewswire/ --

With a growing number of diabetic patients in the country, there is a dire

need for clinics that offer specialized care including lifestyle modification. Wockhardt Hospital, Mumbai Central, a JCI & NABH Accredited hospitals in association with Wellthy Therapeutics, South Asia's leading Digital
Therapeutic company has launched a Diabetes Clinic whose patients will get access to their digital therapeutic suite for Diabetes (WellD).

Digital therapeutics involve the use of clinically validated digital tools or systems to treat chronic medical conditions. Digital technologies such as apps, devices and software are used to treat patients in the same way drugs, surgeries or medical devices are applied therapeutically. Digital therapeutics may be used as stand-alone treatments or as part of a broader treatment program that incorporates both digital and non-digital (conventional) therapies.

Diabetes is a growing challenge in India with an estimated 8.7% diabetic population in the age group of 20 and 70 years. The rising prevalence of diabetes and other non-communicable diseases is driven by a combination of factors - rapid urbanization, sedentary lifestyles, unhealthy diets, tobacco use, and increasing life expectancy. India currently represents 49 per cent of the world's diabetes burden, with an estimated 72 million cases in 2017, a figure expected to almost double to 134 million by 2025. Diabetes prevalence has increased by 64 per cent across India over the last 25 years, according to a November 2017 report by the Indian Council for Medical Research, Institute for Health Metrics and Evaluation, both research institutes, and the Public Health Foundation of India, an advocacy.

Dr. Parag Rindani, Centre Head at Wockhardt Hospital, SOBO, said, "The newly launched Diabetes clinic will be dedicated to provide accessible medical treatment for patients who seek help for various problems related to the disease. Apart from having access to endocrinologists, diabetes foot surgeons, neurologists, internal medicine experts and other specialties, our patients also stand to benefit from continuous and real-time care provided by Wellthy Therapeutics' digital therapeutic suite, as we enable out-of-clinic extensions to our world-class in-clinic care to help our patients improve their health outcomes."

Dr. Behram Pardiwala, Internal Medicine Expert, Wockhardt Hospital, SOBO, said, "Lifestyle modification is the most important component of diabetes care. Patients who follow healthy diets and exercise regularly are better positioned to prevent other complications that result from mismanagement of diabetes."

Wellthy Therapeutics is a digital therapeutics company that empowers patients to prevent, reverse and manage their chronic illnesses. Wellthy's first digital therapeutic for Type-II diabetes has been endorsed by the RSSDI, Asia's largest diabetes research association. The company has published and presented real-world evidence of its outcomes in leading national and international scientific journals and forums. The company has also been featured as a thought leader in diabetes care by the American Diabetes Association.

"Our out-of-clinic, clinically-validated digital therapeutic perfectly complements the state-of-the-art in-clinic care for patients with diabetes at Wockhardt Hospitals. We strongly believe that the combination will enable better patient outcomes and a better quality of life. We are excited to launch this partnership to augment care for all Wockhardt patients and stakeholders," said Abhishek Shah, Co-founder and CEO, Wellthy Therapeutics.

About Wellthy Therapeutics

Wellthy Therapeutics is a digital therapeutics company that aims to prevent, reverse and control the chronic illnesses of millions of patient lives. Its first digital therapeutic for Type II diabetes has been endorsed by Asia's largest diabetes association (RSSDI).

Wellthy Therapeutics has published & presented real-world data at the AACE 26th Annual Congress in Austin and the AACE 27th Annual Congress in Boston, the ADA 77th Scientific Sessions in San Diego and the ADA 78th Scientific Sessions in Florida, the IDF Congress 2017 in Abu Dhabi, the ATTD 11th International Conference in Vienna, the RSSDI 44th & 45th Annual conferences in India, and the 12th RSSDI Regional Conference in India. For more information, visit http://www.wellthy.care.

Media Contact: Reshma Nayak reshma.nayak@wellthy.care +91-9137603901 Wellthy Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store